To ask the Secretary of State for Environment, Food and Rural Affairs, what steps his Department is taking to tackle human health risks associated with spot on pet treatments containing (a) fipronil and (b) imidacloprid.

Veterinary Medicinal Products (VMPs) undergo a thorough assessment by the Veterinary Medicines Directorate (VMD) before they are authorised for marketing in the UK. This includes a product-specific user risk assessment that considers all those that may come into contact with the medicine, including adults and children. This assessment considers the identified hazards of the medicine, the likely exposure to adults and children when VMPs are used as recommended and concludes on the likely risks to humans. The identified risks are mitigated using appropriate packaging and user safety warnings on the product information supplied with the medicines. Once authorised for marketing, pharmacovigilance reporting provides further data from use of these medicines in real-world situations, and these data are used to consider any changes required to reduce identified risks, such as updating the user safety warnings. All VMPs are authorised based on a Benefit:Risk assessment, which accounts for the therapeutic benefits to the treated animals, the potential for reduction of zoonotic diseases in humans, and the possible risks identified to humans and animals. The benefits must outweigh the risks before a product can be authorised and may be removed from the market if shown that this is not the case after authorisation.